Customer Support: 800-526-4902
 

William T. Koustas: Lawyer with Hyman, Phelps & McNamara, P.C.

William T. Koustas

LinkedIn
Associate
Washington,  DC  U.S.A.
Phone(202) 737-9623

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas
  • ......................... 100%
    Food and Drug Law
 
University University of Denver, B.S., Molecular Biology, cum laude, 2003; University of Pennsylvania, M.S., Biotechnology, 2004
 
Law SchoolAmerican University Washington College of Law, J.D., with honors, 2008
 
Admitted2008, Colorado; 2009, District of Columbia
 
BornDenver, Colorado, 1980
 
Biography

Mr. Koustas earned his law degree with honors from American University Washington College of Law in 2008, where he served on the Administrative Law Review from 2006-2008. Mr. Koustas graduated from the University of Pennsylvania in 2004 with a Master of Biotechnology and from the University of Denver in 2003 with a B.S. in Molecular Biology. Mr. Koustas has co-authored several scientific articles on various topics in cancer research. He is admitted to practice in Colorado and the District of Columbia.

Articles / Publications

Trends in FDA's Use of Class-Wide REMS, December 2009

Search Warrants - What Happens When the FDA Storm Arrives, May/June 2009

Blog Posts

Patient Power in Orphan Drugs, January 13, 2013

Red Flags Rule Comes Back, December 5, 2012

Massachusetts Issues Final Rule on Drug and Device Manufacturer Marketing Conduct, November 27, 2012

FDA and California Board of Pharmacy Talk Pedigree at Annual HDMA Track and Trace Conference, November 18, 2012

New Track-and-Trace Legislation: The Real Deal or Another False Start?, October 25, 2012

The Regenerative Sciences - FDA Court Struggle Ends... For Now, July 25, 2012

FDA Continues Efforts to Expand Power Over Intrastate Commerce, October 26, 2011

Regenerative Sciences Lawsuit Update and FDA s Attempt to Broaden the Definition of "Interstate Commerce", October 17, 2011

Government Files Appellate Brief in Purdue Executives' Exclusion Litigation, September 20, 2011

Google to pay $500 Million Regarding Pharmacy Advertising; What is Next?, August 25, 2011

FDA Releases Opioid Class-Wide REMS, April 21, 2011

Red Flags Rule Battle Appears to Come to a Close, March 7, 2011

Regenerative Sciences - FDA Struggle Continues, January 19, 2011

Congress Passes Legislation to Alter Red Flags Rule, December 9, 2010

Confirmation Hearing for Michele Leonhart, Proposed DEA Administrator, November 18, 2010

Secure and Responsible Drug Disposal Act Passes Congress, October 3, 2010

Veterinary Compounding Pharmacy Resumes Operations Despite FDA's Attempt to Obtain a Preliminary Injunction, September 2, 2010

Regenerative Sciences Faced with FDA Injunction, August 11, 2010

FDA Releases Draft of Class-Wide Opioid REMS, July 12, 2010

Regenerative Sciences, Inc. Attempts to Avoid FDA Action, June 27, 2010

FTC Delays Enforcement of the Red Flags Rule&Again, May 28, 2010

FDA Announces a New Class-Wide REMS, February 18, 2010

Kaiser Permanente Submits Citizen Petition on REMS, January 8, 2010

 
ISLN919997484
 

Documents by this lawyer on Martindale.com

Subscribe to this feed

Tracking and Tracing Congress’ New Track and Trace Bills
William T. Koustas,Jessica A. Ritsick, April 26, 2013
Within the last week, members of health committees in the House and Senate unveiled draft bills addressing prescription pharmaceutical supply chain security. The House Energy & Commerce Committee is set to hold a hearing on the House bill on April 25, 2013. Dr. Janet Woodcock, Director of...

Patient Power in Orphan Drugs
William T. Koustas,Frank J. Sasinowski, January 15, 2013
FDASIA/PDUFA V elevates the role of patients in developing orphan therapies. It mandates that FDA implement ways to bring patients' views into drug development and FDA’s regulatory review. This is appropriate as it is often these patients that push development of orphan drugs forward.

Red Flags Rule Comes Back
William T. Koustas, December 7, 2012
The Federal Trade Commission (“FTC”) has amended its Red Flags Rule (“the Rule”) to comply with the Red Flag Program Clarification Act of 2010 (“Clarification Act”). As we have previously reported, the Fair and Accurate Credit Transactions Act of 2003...

Profile Visibility
#1,994 in weekly profile views out of 48,412 lawyers in Washington, District of Columbia
#58,604 in weekly profile views out of 1,500,194 total lawyers Overall

Office Information

William T. Koustas
Hyman, Phelps & McNamara, P.C.
700 Thirteenth Street, N.W., Suite 1200
Washington, DC 20005-5929




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now